Saniona Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Public

  • Employees
  • 45

Employees

  • Stock Symbol
  • SANION

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $1.19
  • (As of Friday Closing)

Saniona General Information

Description

Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune diseases, metabolic diseases, and the treatment of pain. It develops a technology platform that enables the investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. The company product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219. Geographically, it operates in USA, Sweden, Germany, Denmark, and United Kingdom, out of which it derives maximum revenue from USA.

Contact Information

Website
www.saniona.com
Formerly Known As
Aniona
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Murervangen 42
  • 2600 Glostrup
  • Denmark
+45 70
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Stock Exchange
STO
Corporate Office
  • Murervangen 42
  • 2600 Glostrup
  • Denmark
+45 70

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Saniona Stock Performance

As of 13-Nov-2026, Saniona’s stock price is $1.19. Its current market cap is $164M with 138M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.19 $1.19 $0.85 - $3.21 $164M 138M 432K $0.14

Saniona Financials Summary

As of 30-Jun-2026, Saniona has a trailing 12-month revenue of $45.3M.

In Thousands,
USD 		TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 131,482 245,350 82,462 32,214
Revenue 45,337 44,215 31,645 1,584
EBITDA 21,682 31,442 20,809 (7,926)
Net Income 19,598 28,974 17,843 (9,014)
Total Assets 61,850 73,870 30,791 6,418
Total Debt 0 0 952 7,145
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Saniona Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Saniona‘s full profile, request access.

Request a free trial

Saniona Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Saniona AB researches and develops drugs for the treatment of diseases of the central nervous system, autoimmune disease
Drug Delivery
Glostrup, Denmark
45 As of 2026

Millis, MA
 

Framingham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Saniona Competitors (9)

One of Saniona’s 9 competitors is Neuphoria Therapeutics, a Corporate Backed or Acquired company based in Millis, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Neuphoria Therapeutics Corporate Backed or Acquired Millis, MA
Alzheon Venture Capital-Backed Framingham, MA
Alector Formerly VC-backed South San Francisco, CA
Bristol-Myers Squibb Corporation Princeton, NJ
Cerecin Venture Capital-Backed Broomfield, CO
You’re viewing 5 of 9 competitors. Get the full list »

Saniona Patents

  • 7

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

Saniona Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20080234321-A1 1-ethyl-4-[3-fluoro-5-(methylsulfonyl)phenyl]piperidine; central nervous system disorders, parkinson's disease, parkinsonism, dyskinesias, including l-dopa induced dyskinesias, dystonias, tics, tremor, huntington disease Active 13-Oct-2005
US-8501777-B2 1-ethyl-4-[3-fluoro-5-(methylsulfonyl)phenyl]piperidine; central nervous system disorders, parkinson's disease, parkinsonism, dyskinesias, including l-dopa induced dyskinesias, dystonias, tics, tremor, huntington disease Inactive 13-Oct-2005
US-20070149542-A1 1-ethyl-4-[2-fluoro-3-(methylsulfonyl)phenyl]piperidine, havinf therapeutic effects against disorders in the central nervous system, such as dyskinesia Active 08-Jun-2004
US-7763639-B2 1-ethyl-4-[2-fluoro-3-(methylsulfonyl)phenyl]piperidine, havinf therapeutic effects against disorders in the central nervous system, such as dyskinesia Inactive 08-Jun-2004
US-20100256163-A1 Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission Active 08-Jun-2004 C07D211/52
To view Saniona’s complete patent history, request access »

Saniona Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Saniona Investments (4)

Saniona’s most recent deal was a Seed Round with Cephagenix for . The deal was made on 10-Sep-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cephagenix 10-Sep-2025 Seed Round Drug Discovery
Saniona (Headquarters location in Glostrup, Denmark) 19-Jun-2025 Corporate Asset Purchase Buildings and Property
Cephagenix 01-Jan-2020 Joint Venture Drug Discovery
NeuroSearch (Rights in the preclinical and clinical assets) 04-Jul-2017 Corporate Asset Purchase Other Pharmaceuticals and Biotechnology
To view Saniona’s complete investments history, request access »

Saniona ESG

Risk Overview

Risk Rating

Updated October, 31, 2023

36.1 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,766

Rank

Percentile

Pharmaceuticals

Industry

of 891

Rank

Percentile

Pharmaceuticals

Subindustry

of 435

Rank

Percentile

To view Saniona’s complete esg history, request access »

Saniona FAQs

  • When was Saniona founded?

    Saniona was founded in 2011.

  • Where is Saniona headquartered?

    Saniona is headquartered in Glostrup, Denmark.

  • What is the size of Saniona?

    Saniona has 45 total employees.

  • What industry is Saniona in?

    Saniona’s primary industry is Drug Delivery.

  • Is Saniona a private or public company?

    Saniona is a Public company.

  • What is Saniona’s stock symbol?

    The ticker symbol for Saniona is SANION.

  • What is the current stock price of Saniona?

    As of 13-Nov-2026 the stock price of Saniona is $1.19.

  • What is the current market cap of Saniona?

    The current market capitalization of Saniona is $164M.

  • What is Saniona’s current revenue?

    The trailing twelve month revenue for Saniona is $45.3M.

  • Who are Saniona’s competitors?

    Neuphoria Therapeutics, Alzheon, Alector, Bristol-Myers Squibb, and Cerecin are some of the 9 competitors of Saniona.

  • What is Saniona’s annual earnings per share (EPS)?

    Saniona’s EPS for 12 months was $0.14.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process